Co-danthramer

Co-Danthramer is a pharmacological formulation used primarily for the management of constipation, particularly in terminally ill patients. It is a combination medication consisting of Dantron, an anthraquinone stimulant laxative, and Poloxamer 188, a stool softener. Dantron works by stimulating the nerve endings in the colonic mucosa, which in turn activates the muscle movements of the large intestine, facilitating bowel movements. On the other hand, Poloxamer 188 acts as a wetting agent and stool softener, aiding in easing stool passage.

The medication typically begins to exert its laxative effects between 6 to 12 hours after administration. It's available in an oral suspension form and comes in both regular and high-strength dosages. While effective in relieving constipation, Co-Danthramer has specific side effects such as discoloration of urine and potential skin irritation, particularly in incontinent patients. Its use is cautioned in certain populations, including pregnant and nursing mothers, and it is not licensed for patients with non-malignant diseases due to Dantron's potential carcinogenic effects.